SUMMARY Factor VII and prekallikrein activities were studied in 37 patients with liver cirrhosis who were in a decompensated state. Sixteen of them died 30-70 days after admission; 21 survived and were discharged after 30-80 days. Seven who died and six survivors had signs of hyperfibrinolysis: factor VII activity differentiated the two groups independently of the presence of hyperfibrinolysis. The presence of hyperfibrinolysis significantly reduced prekallikrein activity, which did not differentiate clearly survivors from non-survivors. Long term follow up of survivors showed a good correlation between factor VII and prekallikrein activities with long term survival. Hyperfibrinolysis seemed to influence the clinical course of patients: 87% of patients with hyperfibrinolysis who died had fatal haemorrhagic episodes. Low factor VII activity may be a precursor of terminal liver insufficiency.
The prognosis of patients with liver cirrhosis is poor when accompanied by ascites, severe jaundice, haematemesis and prolonged prothrombin time.'
None of these signs, however, can be taken to indicate life expectancy of individual patients,2 or to predict imminent death. Prekallikrein (Prekk) and factor VII activities, two components of the intrinsic and extrinsic coagulation pathways, are sensitive markers of liver failure, when present in very low amounts. ?5 Patients with liver cirrhosis, especially if decompensated, may have hyperfibrinolysis, which may be associated with low grade coagulation system activation6 and can precipitate haemorrhagic episodes.7
Material and methods Cirrhosis of the liver was diagnosed in 37 patients by liver needle biopsy in all but nine patients in whom the risks were too high. In these, diagnosis was based on the presence of the following signs: hepatosplenomegaly, ascites, jaundice, a serum albumin concentration of 30 g/l and prothrombin activity of 40%. The inclusion criteria for LC patients were the clinical and laboratory evidence of a decompensated state defined by the presence ofat least two of the following signs: (i) ascites, (ii) encephalopathy associated with liver disease; (iii) a prothrombin activity of 40%; (iv) a serum Accepted for publication 28 July 1989 albumin concentration of 30 g/l; (v) and a serum bilirubin concentration of 684 ,umol/l.7 Patients with acute hepatis, carcinoma of the liver, and with signs of endotoxaemia were excluded.
Sixteen patients died from liver insufficiency 30-70 days after admission. The remaining 21 survived and were discharged, on average after 30-80 days: they were followed up every six months to evaluate length of survival.
BLOOD COAGULATION STUDY
Blood samples were taken from patients who had fasted for at least 12 hours and mixed with 0a 13 mol/l sodium citrate (ratio 9:1). Normotest (Nyegaard & Co, Oslo) which determines the vitamin K dependent factors II, VII, and X, was performed on whole blood according to the manufacturer's instructions. Prekk plasma activity was evaluated by chromogenic substrate S-2302 (Kabi Diagnostics) using Cephotest (Immuno Diagnostics) as the Prekk activator.8 Intraand interassay coefficients of variation were 3 and 4%, respectively. Factor VII plasma activity was evaluated by chromogenic substrate S-2222 (Kabi Diagnostics) as previously described.9 Intra-and interassay coefficients of variation were 2 and 3%, respectively. Plasminogen plasma activity was investigated by chromogenic substrate S-2251 (Kabi Diagnostics) as previously described.3 Alpha2-antiplasmin plasma activity was determined by Coatest Antiplasmin (Kabi Diagnostics). The end-point method was used to evaluate Prekk, factor VII, plasminogen and alpha2- Of those who died, seven died from gastrointestinal haemorrhage, six of whom were positive for fibrinogen degradation products.
Outcome and hyperfibrinolysis affected the serum activities of Prekk, and factor VII and Normotest results (table 2, figure) . Patients who died from liver insufficiency had significantly lower values of Normotest (variance, 696-324; degree of freedom = 1; Low survivals were seen during follow up of discharged patients: seven died within the first year and eight within the second year. Cause of death was liver insufficiency (n = 9) and bleeding (n = 6). There was a good correlation between Prekk and factor VII activities and length of survival (Prekk: r = 0-899; factor VII: r = 0-804, p < 0-001).
Discussion
Length of survival in cirrhosis of the liver depends on the degree of liver insufficiency: compensated patients survive longer than those who are decompensated. 2 The five year survival of decompensated patients is very low, reaching values of 34% when patients have ascites, jaundice, and haematemesis.2 The one year survival of our patients (38%) is lower than that previously reported.'2"3 This is probably due to the inclusion criteria which selected patients with high degree of decompensation. Even if clinical data are useful to predict the prevalence of liver cirrhosis, the assessment of individual patients is very difficult.2 This is supported by our data which were comparable for survivors and non-survivors, except for much higher values of serum bilirubin in non-survivors.
The assessment of whether death in decompensated patients with cirrhosis is imminent is important in view of identifying patients as candidates for liver transplantation. Many coagulation factors, synthesised by liver cells, have been previously identified as markers of liver insufficiency. A previous study suggested that plasminogen, factor V, and factor XII were lower in non-survivors than in survivors, but these two subgroups were not clearly differentiated.'4 Factor VIIP0 and Prekk5'5 activities were previously indicated as markers for the assessment of individual patients with acute as well as chronic liver disease. Because chronic liver disease can be complicated by hyperfibrinolysis,'6 we studied the influence of this clotting abnormality on the prognostic value of factor VII and Prekk.
Our findings suggest that factor VII is a good prognostic indicator of liver failure whether or not patients had hyperfibrinolysis. Indeed, hyperfibrinolysis did not influence the factor VII activity in either group. The importance of factor VII as a prognostic indicator of liver insufficiency was particularly emphasised by the statistical difference between nonsurvivors without hyperfibrinolysis and survivors with hyperfibrinolysis. Prekk activity and Normotest results, on the other hand, did not differentiate survivors from non-survivors owing to the significant reduction in their activity caused by hyperfibrinolysis. Prekk activity could be a useful marker of liver insufficiency in long term follow up, however. Prekk and factor VII activities were significantly correlated with the length of survival of discharged patients.
The clinical course of inpatients was complicated by fatal haemorrhagic episodes predominantly in patients with hyperfibrinolysis. This could therefore'7 precipitate haemorrhagic episodes, probably through the consumption of blood clotting factors. The identification of the mechanisms leading to hyperfibrinolysis could be useful for the future management of cirrhosis of the liver.
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